OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma

Xiangxuan Zhao, Changhai Tian, William M. Puszyk, Olorunseun O. Ogunwobi, Mengde Cao, Ton Wang, Roniel Cabrera, David R. Nelson, Chen Liu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood. In this study, we show that sorafenib triggers cell growth inhibition and apoptosis in HCC cells by directly targeting the mitochondria. Treatment with sorafenib induces rapid mitochondrial fragmentation, which is associated with the deregulation of mitochondria fusion-related protein optic atrophy 1 (OPA1). Exposure of cells or isolated mitochondria to sorafenib substantially induces cytochrome c release. Our data indicate that siRNA-mediated OPA1 knockdown significantly sensitizes HCC cells to sorafenib-induced apoptosis. Furthermore, sorafenib has no apparent apoptotic toxicity to normal human primary hepatocytes. Sorafenib inhibits HCC xenograft tumor growth in vivo and murine xenograft tumor tissue analysis reveals mitochondria fusion protein. OPA1 expression levels are strongly downregulated by sorafenib treatment. Western blotting evaluation of patient HCC with matched non-tumor tissue samples demonstrates that OPA1 expression is decreased in up to 40% of HCC patients. Taken together, we have shown that sorafenib suppresses the tumorigenesis of HCC through the induction of mitochondrial injury via OPA1. Our results provide new insights into the pathogenesis of HCC and suggest that OPA1 is a novel therapeutic target in patients with HCC.

Original languageEnglish (US)
Pages (from-to)8-19
Number of pages12
JournalLaboratory Investigation
Volume93
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Autosomal Dominant Optic Atrophy
Hepatocellular Carcinoma
Down-Regulation
Apoptosis
Mitochondria
Heterografts
sorafenib
Therapeutics
Growth
Cytochromes c
Small Interfering RNA
Hepatocytes
Neoplasms
Carcinogenesis
Proteins
Western Blotting

Keywords

  • OPA1
  • apoptosis
  • liver cancer
  • mitochondria fragmentation
  • sorafenib

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. / Zhao, Xiangxuan; Tian, Changhai; Puszyk, William M.; Ogunwobi, Olorunseun O.; Cao, Mengde; Wang, Ton; Cabrera, Roniel; Nelson, David R.; Liu, Chen.

In: Laboratory Investigation, Vol. 93, No. 1, 01.01.2013, p. 8-19.

Research output: Contribution to journalArticle

Zhao, X, Tian, C, Puszyk, WM, Ogunwobi, OO, Cao, M, Wang, T, Cabrera, R, Nelson, DR & Liu, C 2013, 'OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma', Laboratory Investigation, vol. 93, no. 1, pp. 8-19. https://doi.org/10.1038/labinvest.2012.144
Zhao, Xiangxuan ; Tian, Changhai ; Puszyk, William M. ; Ogunwobi, Olorunseun O. ; Cao, Mengde ; Wang, Ton ; Cabrera, Roniel ; Nelson, David R. ; Liu, Chen. / OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. In: Laboratory Investigation. 2013 ; Vol. 93, No. 1. pp. 8-19.
@article{0af224e131da42daab349978ecdfbbb7,
title = "OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma",
abstract = "Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood. In this study, we show that sorafenib triggers cell growth inhibition and apoptosis in HCC cells by directly targeting the mitochondria. Treatment with sorafenib induces rapid mitochondrial fragmentation, which is associated with the deregulation of mitochondria fusion-related protein optic atrophy 1 (OPA1). Exposure of cells or isolated mitochondria to sorafenib substantially induces cytochrome c release. Our data indicate that siRNA-mediated OPA1 knockdown significantly sensitizes HCC cells to sorafenib-induced apoptosis. Furthermore, sorafenib has no apparent apoptotic toxicity to normal human primary hepatocytes. Sorafenib inhibits HCC xenograft tumor growth in vivo and murine xenograft tumor tissue analysis reveals mitochondria fusion protein. OPA1 expression levels are strongly downregulated by sorafenib treatment. Western blotting evaluation of patient HCC with matched non-tumor tissue samples demonstrates that OPA1 expression is decreased in up to 40{\%} of HCC patients. Taken together, we have shown that sorafenib suppresses the tumorigenesis of HCC through the induction of mitochondrial injury via OPA1. Our results provide new insights into the pathogenesis of HCC and suggest that OPA1 is a novel therapeutic target in patients with HCC.",
keywords = "OPA1, apoptosis, liver cancer, mitochondria fragmentation, sorafenib",
author = "Xiangxuan Zhao and Changhai Tian and Puszyk, {William M.} and Ogunwobi, {Olorunseun O.} and Mengde Cao and Ton Wang and Roniel Cabrera and Nelson, {David R.} and Chen Liu",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/labinvest.2012.144",
language = "English (US)",
volume = "93",
pages = "8--19",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma

AU - Zhao, Xiangxuan

AU - Tian, Changhai

AU - Puszyk, William M.

AU - Ogunwobi, Olorunseun O.

AU - Cao, Mengde

AU - Wang, Ton

AU - Cabrera, Roniel

AU - Nelson, David R.

AU - Liu, Chen

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood. In this study, we show that sorafenib triggers cell growth inhibition and apoptosis in HCC cells by directly targeting the mitochondria. Treatment with sorafenib induces rapid mitochondrial fragmentation, which is associated with the deregulation of mitochondria fusion-related protein optic atrophy 1 (OPA1). Exposure of cells or isolated mitochondria to sorafenib substantially induces cytochrome c release. Our data indicate that siRNA-mediated OPA1 knockdown significantly sensitizes HCC cells to sorafenib-induced apoptosis. Furthermore, sorafenib has no apparent apoptotic toxicity to normal human primary hepatocytes. Sorafenib inhibits HCC xenograft tumor growth in vivo and murine xenograft tumor tissue analysis reveals mitochondria fusion protein. OPA1 expression levels are strongly downregulated by sorafenib treatment. Western blotting evaluation of patient HCC with matched non-tumor tissue samples demonstrates that OPA1 expression is decreased in up to 40% of HCC patients. Taken together, we have shown that sorafenib suppresses the tumorigenesis of HCC through the induction of mitochondrial injury via OPA1. Our results provide new insights into the pathogenesis of HCC and suggest that OPA1 is a novel therapeutic target in patients with HCC.

AB - Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood. In this study, we show that sorafenib triggers cell growth inhibition and apoptosis in HCC cells by directly targeting the mitochondria. Treatment with sorafenib induces rapid mitochondrial fragmentation, which is associated with the deregulation of mitochondria fusion-related protein optic atrophy 1 (OPA1). Exposure of cells or isolated mitochondria to sorafenib substantially induces cytochrome c release. Our data indicate that siRNA-mediated OPA1 knockdown significantly sensitizes HCC cells to sorafenib-induced apoptosis. Furthermore, sorafenib has no apparent apoptotic toxicity to normal human primary hepatocytes. Sorafenib inhibits HCC xenograft tumor growth in vivo and murine xenograft tumor tissue analysis reveals mitochondria fusion protein. OPA1 expression levels are strongly downregulated by sorafenib treatment. Western blotting evaluation of patient HCC with matched non-tumor tissue samples demonstrates that OPA1 expression is decreased in up to 40% of HCC patients. Taken together, we have shown that sorafenib suppresses the tumorigenesis of HCC through the induction of mitochondrial injury via OPA1. Our results provide new insights into the pathogenesis of HCC and suggest that OPA1 is a novel therapeutic target in patients with HCC.

KW - OPA1

KW - apoptosis

KW - liver cancer

KW - mitochondria fragmentation

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84871772322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871772322&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2012.144

DO - 10.1038/labinvest.2012.144

M3 - Article

VL - 93

SP - 8

EP - 19

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 1

ER -